Study of the effectiveness of voriconazole in the treatment of Aspergillus fumigatus associated asthma

Not Applicable

Completed

• Conditions: Asthma; Respiratory

• Registration Number: ISRCTN42366088
• Lead Sponsor: niversity Hospitals of Leicester NHS Trust (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2009-01-30
• Last Update Posted: 17 October 2016

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

1. Symptoms consistent with a diagnosis of asthma
2. A clinical phenotype consistent with AF associated asthma in the opinion of at least two consultant members of the study team
3. Evidence of immune sensitisation to AF (either positive AF IgE, positive SPT to AF or positive AF IgG)
4. A raised peripheral blood eosinophil count or sputum eosinophil count of more than 10% on at least one occasion in the last two years
5. AF in sputum on two occasions within the six months prior to entry into the study
6. At least two severe exacerbations in the previous 12 months (defined as a requirement for a course of high dose oral steroids for treatment of their asthma)
7. Aged above 18 years, both male and female

Exclusion Criteria

1. Unable to give informed consent
2. Pregnancy or possibility of becoming pregnant during the treatment phase of the study
3. A primary diagnosis (in the opinion of the study team) of chronic obstructive pulmonary disease (COPD) (smoking related obstructive disease)
4. Any conditions or drug interactions that in the opinion of the study team could lead to harmful interactions with voriconazole
5. Allergy to voriconazole
6. Poor compliance
7. Inability to produce sputum

Study & Design

• Study Type: Interventional
• Study Design: Not specified